The estimated Net Worth of Arthur Taveras is at least $239 mil dollars as of 11 March 2024. Arthur Taveras owns over 14,235 units of X4 Pharmaceuticals stock worth over $161,668 and over the last 4 years he sold XFOR stock worth over $77,719. In addition, he makes $0 as Chief Scientific Officer at X4 Pharmaceuticals.
Arthur has made over 5 trades of the X4 Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 14,235 units of XFOR stock worth $12,527 on 11 March 2024.
The largest trade he's ever made was selling 67,695 units of X4 Pharmaceuticals stock on 1 November 2023 worth over $49,417. On average, Arthur trades about 8,371 units every 33 days since 2020. As of 11 March 2024 he still owns at least 234,301 units of X4 Pharmaceuticals stock.
You can see the complete history of Arthur Taveras stock trades at the bottom of the page.
Dr. Arthur Taveras Ph.D. serves as Chief Scientific Officer of the Company. serves as Chief Scientific Officer of the Company. Dr. Taveras brings more than 30 years of experience leading small molecule research and development programs focused on the treatment of cancer, dysregulated immune disorders, neurodegeneration and metabolic diseases. His research and leadership have led to the development of multiple clinical candidates and dozens of clinical trials. He joins X4 from CoMET Therapeutics, where he served as Chief Scientific Officer. Previously, he was the Founder and Chief Scientific Officer at Transform Therapeutics, a company aiming to discover CXCR2 antagonists for the treatment of cancer, and served as President and Chief Scientific Officer at ShangPharma ChemPartner where he supported the discovery initiatives and clinical portfolios of hundreds of pharmaceutical and biotech companies worldwide. Prior to that, Dr. Taveras was Vice President of Small Molecule Drug Discovery and CMC Development at Biogen Idec, and Alantos Pharmaceuticals, which was acquired by Amgen in 2007. Dr. Taveras began his career with Schering-Plough Corporation and held multiple roles of increasing responsibility in the oncology and immunology drug discovery and research sector over a 14-year period including leading the discovery of Navarixin®, a CXCR2 antagonist currently in clinical trials in combination with pembrolizumab for the treatment of cancer. He holds 130 issued patents and patent applications and has authored more than 90 scientific publications. Dr. Taveras received his B.S., M.S. and Ph.D. from Rensselaer Polytechnic Institute.
Arthur's mailing address filed with the SEC is C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON, MA, 02134.
Over the last 6 years, insiders at X4 Pharmaceuticals have traded over $2,179,690 worth of X4 Pharmaceuticals stock and bought 25,000 units worth $30,000 . The most active insiders traders include Paula Ragan, Adam S. Mostafa, eGary Bridger. On average, X4 Pharmaceuticals executives and independent directors trade stock every 19 days with the average trade being worth of $12,232. The most recent stock trade was executed by Mary Di Biase on 9 September 2024, trading 2,642 units of XFOR stock currently worth $1,744.
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
X4 Pharmaceuticals executives and other stock owners filed with the SEC include: